Drugs / MDMA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05809271 | Nov 2023 → Mar 2025 | — | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MDMA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05809271 ↗ |
| Route | Oral | “An oral dose of 120 mg racemic MDMA will be administered followed by a second dose of 60 mg racemic MDMA two hours later.” NCT05809271 ↗ |